We read with interest the recent study by Salem et al1 providing evidence from a randomized phase II trial of patients with hepatocellular carcinoma (HCC) that Y90 radioembolization is associated with significantly longer median time to progression (TTP) than conventional transarterial chemoembolization (TACE). Both Y90 radioembolization and TACE are widely used as “bridge” therapies that can postpone the need for other treatments, such as liver resection or transplantation, in patients with numerous or bulky HCC tumors.